{"_id": "64ff8e8e8ed67004cfc73a8d", "nctID": "NCT04729959", "booleanRepresentation": "{\n    \"$and\": [\n        {\n            \"$and\": [\n                {\n                    \"$or\": [\n                        {\"Histopathologically proven diagnosis of glioblastoma\"},\n                        {\"molecular diagnosis of glioblastoma per Consortium to Inform Molecular and Practical Approaches to Central Nervous System Tumor Taxonomy (c-IMPACT-NOW) criteria\"}\n                    ]\n                },\n                {\"Tumor that is in first recurrence following prior first-line radiation therapy (prior dose >= 40 Gy)\"}\n            ]\n        },\n        {\"Unequivocal radiographic evidence of tumor progression by contrast-enhanced magnetic resonance imaging (MRI) scan within 21 days prior to registration\"},\n        {\n            \"$and\": [\n                {\"Per radiation oncologist review of MRI within 21 days prior to registration\"},\n                {\n                    \"$and\": [\n                        {\"At least 1 cm x 1 cm contrast-enhancing tumor that is no greater than 4 cm in largest dimension\"},\n                        {\"FSRT target is at least 0.5 cm from the optic chiasm and brainstem\"}\n                    ]\n                },\n                {\"Note, multifocal disease (i.e., other sites of tumor beyond the tumor being targeted for FSRT) is allowed if the above criteria are met for the tumor that is the proposed target for FSRT\"}\n            ]\n        },\n        {\n            \"$and\": [\n                {\"Surgical cohort only (Phase II only)\"},\n                {\"Must be a candidate for repeat surgery (significant debulking or gross total resection of the contrast enhancing area) as determined by the neurosurgeon or multidisciplinary team\"}\n            ]\n        },\n        {\"Tumor O-6-methylguanine-deoxyribonucleic acid (DNA) methyltransferase (MGMT) methylation status must be available from any prior GBM tumor specimen; results of routinely used methods for MGMT methylation testing (e.g. mutagenically separated polymerase chain reaction [MSPCR] or quantitative polymerase chain reaction [PCR]) are acceptable)\"},\n        {\n            \"$and\": [\n                {\"The following intervals from previous treatments to registration are required to be eligible:\"},\n                {\n                    \"$and\": [\n                        {\"If prior radiation was < 60 Gy,"}